Search the Newsreel

Proto Labs Inc stock hits 52-week high at 92.0 USD

Proto Labs Inc. (PRLB) shares have reached a new 52-week high of $92.00, driven by an impressive 90% total return over the past year and nearly 79% year-to-date. This growth follows strong Q2 results, exceeding analyst expectations with record revenue and adjusted earnings, and …

Baron Discovery Fund’s Strategic Trim of Establishment Labs Holdings Inc (ESTA) Locks Gains

Baron Capital, an investment management company, released its Q2 2026 investor letter for the "Baron Discovery Fund". A copy of the letter is available to download here. Baron Discovery Fund appreciated by 19.08% (Institutional Shares) in the quarter, underperforming the Russell 2000 Growth Index, …

H.C. Wainwright cuts Shattuck Labs stock price target on trial expansion

H.C. Wainwright has lowered its price target for Shattuck Labs (NASDAQ:STTK) to $14 from $18, while maintaining a Buy rating, following the company's Q2 2026 financial results and an expanded Phase 2b trial for its lead asset, SL-325. Despite the price target cut, the …

Needham Maintains Shattuck Labs(STTK.US) With Buy Rating, Maintains Target Price $17

Needham has reiterated its Buy rating for Shattuck Labs (STTK.US) and maintained its price target at $17. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance and potential.

BioAge Labs, Inc. (NASDAQ:BIOA) Receives Consensus Rating of "Moderate Buy" from Analysts

BioAge Labs, Inc. (NASDAQ:BIOA) has received a "Moderate Buy" consensus rating from analysts, with six out of seven recommending a buy and one a sell. The average 12-month price target is $36.57, though recent targets vary from $21 to $40. The company reported a …

Tema ETFs LLC Has $52.71 Million Stake in Planet Labs PBC $PL

Several Insiders Invested In Shattuck Labs Flagging Positive News

Several insiders at Shattuck Labs (NASDAQ:STTK) have recently bought shares, with one independent director purchasing US$250k worth. While this buying activity occurred at a price below current market value, it suggests insiders view the company's prospects positively. Despite a recent loss, the substantial insider …

Australian Clinical Labs (ASX:ACL) Value Case Builds as Healthcare Stock Reprices

Form 8K Shattuck Labs Inc For: 11 August By Investing.com

This article announces that Shattuck Labs Inc. filed a Form 8K on August 11, according to Investing.com. The brief news item includes the company's stock symbol STTK and its positive performance for the day. No further details about the content of the Form 8K …

MOBIX LABS, INC. (MOBX) Earnings Forecast: Future EPS & Revenue Growth Estimates

GeoVax targets Q4 phase 3 trial for MVA mpox vaccine with EMA expedited pathway

GeoVax Labs Inc. is preparing to initiate a pivotal phase 3 trial for its GEO-MVA mpox and smallpox vaccine candidate by the end of 2024, following an expedited regulatory pathway granted by the European Medicines Agency (EMA). The EMA waived phase 1 and 2 …

Jyothy Labs Q1 Results: Net Profit Slumps 51% As Margin Shrinks, Revenue Up 3% YoY; Stock Falls 4%

Nano Labs (NA) Dips 1.09% to $1.81, Testing Key Support Near $1.72 - Scalping Stock Signals

Lyka Labs standalone profit surges 159% in Q1FY27 on export strength

VivoSim Labs Ord Shs (VIVS) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for VivoSim Labs Ord Shs (VIVS), detailing its current stock performance, market capitalization, and P/E ratio. It also lists peer comparisons with other biotechnology and medical research companies, indicating the number of ratings and analysts for each. The …

Is Shattuck Labs Inc (STTK) Overvalued Following Q2 Earnings Mis

Establishment Labs Holdings Inc. (NASDAQ:ESTA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$102

Establishment Labs Holdings Inc. (NASDAQ:ESTA) saw its stock drop 17% last week after releasing earnings, despite revenues beating expectations by 2.7%. Analysts have updated their forecasts, maintaining revenue estimates but increasing per-share loss expectations, yet they still raised the average price target by 7.1% …

Proto Labs (PRLB) Is Up 11.7% After Raising 2026 Revenue Guidance And Highlighting Rising Customer Spend

In late July 2026, Proto Labs, Inc. reported past second-quarter results showing sales of US$149.34 million and net income of US$9.15 million, alongside raising its full-year 2026 revenue growth guidance to 8%–10% and issuing new third-quarter earnings guidance. Management highlighted a 17% year-over-year increase …

STTK Maintained by HC Wainwright & Co. -- Price Target Lowered to $14

HC Wainwright & Co. has maintained a 'Buy' rating for Shattuck Labs (STTK) but lowered its price target from $18.00 to $14.00, reflecting a cautious outlook due to the company's significant overvaluation, low profitability, and mixed insider sentiment. Despite developing innovative therapies, the stock …

HC Wainwright Cuts Shattuck Labs (NASDAQ:STTK) Price Target to $14.00

HC Wainwright has reduced its price target for Shattuck Labs (NASDAQ:STTK) to $14.00 from $18.00, while maintaining a "buy" rating, indicating a potential upside of approximately 94%. Despite the lowered target, analysts collectively give the company a "Moderate Buy" rating with an average target …

Astera Labs Posted 104% Revenue Growth in Q2. Why Is ALAB Down From Its Highs?

Astera Labs (ALAB) reported strong Q2 revenue growth of 104% year-over-year, beating analyst expectations, and provided optimistic Q3 guidance. Despite this strong performance and raised analyst targets, the stock is down from its highs, trading at a high valuation multiple. The company's growth drivers …

Shattuck Labs 2Q Loss/Shr 12c >STTK

Shattuck Labs (STTK) reported a second-quarter loss per share of 12 cents. Further details regarding their financial performance were not provided in this brief announcement.

Astera Labs Inc (Derivatives): Latest News, Social Media Updates and Insights

This article provides the latest news and social media updates for Astera Labs Inc (Derivatives). It highlights that 12 Nasdaq 100 stocks, including Sandisk, have more than doubled in 2026, with none of them being part of the "Magnificent Seven" group. The article also …

Astera Labs, Inc. (ALAB) Stock Price, News, Quote & History

This page provides a comprehensive overview of Astera Labs, Inc. (ALAB) stock, including its current price, historical data, key financial metrics, and analyst insights. The stock closed at $311.99 on August 11, with pre-market trading showing a rise to $318.03. Astera Labs specializes in …

Can MRVL's NVDA Alliance Help it Challenge ALAB & AVGO?

Marvell Technology MRVL and NVIDIA NVDA are collaborating on advanced networking and optical technologies. Their expanded partnership includes silicon photonics and advanced optical interconnect solutions, areas in which MRVL has established capabilities in optical DSPs, silicon photonics and high-speed connectivity, and NVIDIA has NVLink …

Shattuck Labs (NASDAQ:STTK) Releases Earnings Results, Hits Expectations

Australian Clinical Labs Limited (ASX:ACL) Share Market Overview and Healthcare Sector Profile

Shattuck Labs posts investor deck spotlighting DR3-blocking antibody SL-325 for inflammatory diseases

Shattuck Labs has released an investor deck detailing its strategy to develop DR3-blocking antibodies, primarily SL-325, for inflammatory and immune-mediated diseases. A Phase 2b trial for SL-325 in Crohn's disease is set to begin in Q3 2026, with initial data expected in 1H 2028. …

GeoVax Highlights Gedeptin(R) Tumor-Priming Strategy as Immuno-Oncology Enters New Phase

GeoVax is highlighting its Gedeptin(R) therapy as a tumor-priming strategy following the FDA's accelerated approval of Replimune's intratumoral therapy TUDRIQEV in combination with nivolumab. GeoVax believes this approval reinforces the paradigm that local tumor destruction can enhance immune responses, an area where Gedeptin, a …

Astera Labs vs. Arm: Which Technology Stock Is a Better Buy in 2026?

As artificial intelligence demands higher performance, investors are weighing the explosive growth of Astera Labs (NASDAQ:ALAB) against the architectural dominance of Arm (NASDAQ:ARM) to find the superior long-term play. While both companies are essential to the modern computing ecosystem, they occupy different niches. Astera …

Shattuck Labs Q2 Results: EPS misses estimate, losses widen 50% YoY

Shattuck Labs Reports $15.2 Million Q2 Loss and 2029 Cash Runway

Shattuck Labs (STTK) reported a Q2 2026 net loss of $15.2 million, with $0 revenue, and expects its $208.3 million in cash to fund operations into 2029. The company provided updates on its SL-325 clinical trial, with Phase 2b starting in Q3 2026, and …

Amagi Media Labs expands TV9 partnership for full CTV operations

Shattuck Labs GAAP EPS of -$0.12 in-line

* Shattuck Labs press release [https://seekingalpha.com/pr/20614116-shattuck-labs-reports-second-quarter-2026-financial-results-and-recent-business-highlights] (STTK [https://seekingalpha.com/symbol/STTK]): Q2 GAAP EPS of -$0.12 in-line. * As of June 30, 2026, cash and cash equivalents, and short-term investments, were approximately $208.3 million. Shattuck’s current cash and cash equivalents, and short-term investments are expected to fund …

Aarti Pharmalabs Hits ₹868 Bull Target; Gains 15.6%

Renaissance Technologies LLC Buys 120,188 Shares of BioAge Labs, Inc. $BIOA

Renaissance Technologies LLC significantly increased its stake in BioAge Labs, Inc. (NASDAQ:BIOA) by 653.2% in the first quarter, acquiring an additional 120,188 shares, bringing its total to 138,588 shares valued at approximately $2.42 million. Other institutional investors also added to their positions. Despite reporting …